In a rare dual operation, a 55-year-old woman from Uttar Pradesh underwent back-to-back surgeries for a malignant tumour in her breast and a benign one in the heart at a private hospital here, doctors said on Thursday.
The patient was admitted to the hospital with a cancer in her right breast. A CT scan of her chest revealed clear lungs, but a malignant mass in her breast and something in her heart (left atrium) which was asymptomatic, the hospital said in a statement.
"A team of doctors from Fortis Hospital, Vasant Kunj in south Delhi, consisting of oncologists, cardiologists, radiologists, anesthesiologists and critical care specialists, conducted simultaneous open-heart surgery and segmental mastectomy under general anaesthesia on the 55-year-old patient from Gorakhpur," it said.
This form of dual surgery is "rare and the first of its kind," the hospital claimed, saying the surgery was conducted recently.
The doctors said the cardiology team's tests suggested that the mass or lesion in the heart was an atrial myxoma, a benign cardiac tumour.
With the presentation of evidence of two separate tumours -- one in the breast and one in the heart -- treatment options were narrowed, they said.
More From This Section
The team assessed the situation as the malignant tumour in the breast needed to be treated urgently and treatment involved surgery, chemotherapy, targeted immunotherapy, radiation and hormonal therapy.
The treating team consisted of Dr. Mandeep Malhotra, Dr. Tapan Ghose and Dr. Sanjay Gupta.
Sanjay Gupta, Director, Cardiac Surgery and Cardio Thoracic Vascular Surgery at the hospital, said, "Another challenge under the circumstances was that immunotherapy and certain chemotherapeutic drugs, sometimes cause weakening of heart, therefore heart function should be at its optimum best to withstand the treatment".
Mandeep Malhotra, Head, Department of Head Neck and Breast Oncoplasty at the hospital, said, "The histopathology of the patient proved that she was suffering from stage 3 breast cancer with an atrial myxoma. Profiling showed that she was an ideal candidate for targeted therapy in the form of Trazatususmab, which often causes weakening of the heart."